1.Ahmadi Ghezeldasht S, Shirdel A, Assarehzadegan MA, Hassannia T, Rahimi H, Miri R, Rezaee SA: Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL). Iranian journal of basic medical sciences 2013, 16(3):179–195.
2.Treviño A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM, Hernandez A, Calderón E, Rodríguez M, Torres A: Trends in the prevalence and distribution of HTLV–1 and HTLV–2 infections in Spain. Virology journal 2012, 9(1):71.
3.Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, Sohgandi L, Azarpazhooh MR, Rezaee SA, Farid R: High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. Journal of Clinical Virology 2011, 52(3):172–176.
4.Boostani R, Vakili R, Hosseiny SS, Shoeibi A, Fazeli B, Etemadi MM, Sabet F, Valizade N, Rezaee SA: Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV–1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV–1-Associated Myelopathy/Tropical Spastic Paraparesis. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics 2015, 12(4):887–895.
5.Tsukasaki K, Tobinai K: Biology and treatment of HTLV–1 associated T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26(1):3–14.
6.Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, Ho A, Devereux S, Mufti GJ, Pagliuca A: Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leukemia research 2012, 36(7):857–861.
7.Roodman GD: Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997, 80(S8):1557–1563.
8.Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M: Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood 2002, 99(2):634–640.
9.Kiyokawa T, Yamaguchi K, Takeya M, Takahashi K, Watanabe T, Matsumoto T, Lee SY, Takatsuki K: Hypercalcemia and osteoclast proliferation in adult T‐cell leukemia. Cancer 1987, 59(6):1187–1191.
10.Peter SA, Cervantes JF: Hypercalcemia associated with adult T-cell leukemia/lymphoma (ATL). J Natl Med Assoc 1995, 87(10):746–748.
11.Shirakawa F, Yamashita U, Oda S, Chiba S, Eto S, Suzuki H: Calcium dependency in the growth of adult T-cell leukemia cells in vitro. Cancer research 1986, 46(2):658–661.
12.Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma. British journal of haematology 1991, 79(3):428–437.
13.Ramezani S, Shirdel A, Rafatpanah H, Akbarin MM, Tarokhian H, Rahimi H, Bari A, Jahantigh HR, Rezaee SA: Assessment of HTLV–1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma. Medical microbiology and immunology 2017, 206(4):327–335.
14.Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. Journal of Clinical Oncology 2010, 28(27):4177–4183.
15.Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington Jr W, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. Journal of Clinical Oncology 2009, 27(3):453–459.
16.Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M: Prognostic index for acute-and lymphoma-type adult T-cell leukemia/lymphoma. Journal of Clinical Oncology 2012, 30(14):1635–1640.
17.Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N: Treatment and survival among 1594 patients with ATL. Blood 2015, 126(24):2570–2577.
18.Sawada Y, Hino R, Hama K, Ohmori S, Fueki H, Yamada S, Fukamachi S, Tajiri M, Kubo R, Yoshioka M: Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 2011, 117(15):3961–3967.
19.Ishitsuka K, Ikeda S, Utsunomiya A, Saburi Y, Uozumi K, Tsukasaki K, Etou Ki, Muta K, Ohno Y, Kinosita Ki: Smouldering adult T‐cell leukaemia/lymphoma: a follow‐up study in Kyushu. British journal of haematology 2008, 143(3):442–444.
20.Setoyama M, Katahira Y, Kanzaki T: Clinicopathologic Analysis of 124 Cases of Adult T‐Cell Leukemia/Lymphoma with Cutaneous Manifestations: The Smouldering Type with Skin Manifestations Has a Poorer Prognosis than Previously Thought. The Journal of dermatology 1999, 26(12):785–790.
21.Yamaguchi T, Ohshima K, Karube K, Tutiya T, Kawano R, Suefuji H, Shimizu A, Nakayama J, Suzumiya J, Moroi Y: Clinicopathological features of cutaneous lesions of adult T‐cell leukaemia/lymphoma. British Journal of Dermatology 2005, 152(1):76–81.
22.Bittencourt AL, Vieira MdG, Brites CR, Farre L, Barbosa HS: Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. American Journal of Clinical Pathology 2007, 128(5):875–882.
23.Yves P, Stephane M, Rishika B, Christine D, Gérard P: Characteristics of adult T-Cell leukemia/lymphoma patients with long survival: prognostic significance of skin lesions and possible beneficial role of valproic acid. Leukemia research and treatment 2015, 2015.
24.Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M: Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. Journal of Clinical Oncology 2019:JCO. 18.00889.
25.Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. New England Journal of Medicine 1995, 332(26):1749–1751.
26.Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, Kumaran T, Ardeshna KM, Pagliuca A, Taylor GP: Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. Journal of Clinical Oncology 2011, 29(35):4696–4701.
27.Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H et al: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113(26):6528–6532.
28.Kchour G, Rezaee R, Farid R, Ghantous A, Rafatpanah H, Tarhini M, Kooshyar MM, El Hajj H, Berry F, Mortada M et al: The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology 2013, 10:91.
29.Tsukasaki K, Tobinai K: Clinical Trials and Treatment of ATL. Leuk Res Treatment 2012, 2012:101754.
30.Kawano N, Yoshida S, Kuriyama T, Tahara Y, Yamashita K, Nagahiro Y, Kawano J, Koketsu H, Toyofuku A, Manabe T: Clinical features and treatment outcomes of 81 patients with aggressive type adult T-cell leukemia-lymphoma at a single institution over a 7-year period (2006–2012). Internal Medicine 2015, 54(12):1489–1498.
31.Phillips AA, Shapira I, Willim RD, Sanmugarajah J, Solomon WB, Horwitz SM, Savage DG, Bhagat G, Soff G, Zain JM: A critical analysis of prognostic factors in North American patients with human T‐cell lymphotropic virus type‐1‐associated adult T‐cell leukemia/lymphoma. Cancer 2010, 116(14):3438–3446.
32.Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T, Ohshima R, Kuwabara H, Tanaka M, Tomita N: Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. International journal of hematology 2013, 98(2):258–260.
33.Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M: Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010:blood–2009–2010–247510.
34.Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M: Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012, 119(9):2141–2148.
35.Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y: Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012, 120(8):1734–1741.
36.Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Taniguchi S, Utsunomiya A, Sobue T, Matsuo K: Association between decreasing trend in the mortality of adult T-cell leukemia/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT). Blood cancer journal 2013, 3(11):e159.
37.Arima N, Hidaka S, Fujiwara H, Matsushita K, Ohtsubo H, Arimura K, Kukita T, Fukumori J, Tanaka H: Relation of autonomous and interleukin–2-responsive growth of leukemic cells to survival in adult T-cell leukemia. Blood 1996, 87(7):2900–2904.
38.Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, Tara M, Kawano F, Saburi Y, Kikuchi H: Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation 2001, 27(1):15.
39.Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leukemia research 2007, 31(6):751–757.
40.Tsukasaki K, Tobinai K: Human T-cell lymphotropic virus type I–associated adult T-cell leukemia–lymphoma: new directions in clinical research. In.: AACR; 2014.
41.Group LS: Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leukemia research 1991, 15(2–3):81–90.
42.Humans IWGotEoCRt, Cancer IAfRo: Human immunodeficiency viruses and human T-cell lymphotropic viruses, vol. 67: World Health Organization; 1996.
43.Matsushita K, Matsumoto T, Ohtsubo H, Fujiwara H, Imamura N, Hidaka S, Kukita T, Tei C, Matsumoto M, Arima N: Long-term Maintenance Combination Chemotherapy with OPECMPEC (Vincristine or Methotrexate, Prednisolone, Etoposide and Cyclophosphamide) or with Daily Oral Etoposide and Prednisolone Can Improve Survival and Quality of Life in Adult T-cell LeukemiaLymphoma. Leukemia & Lymphoma 1999, 36(1–2):67–75.
44.Shimamoto Y, Ono K, Sano M, Matsuzaki M, Suga K, Sueoka E, Tokioka T, Yamaguchi M, Suzuki H, Sato H: Differences in prognostic factors between leukemia and lymphoma type of adult t‐cell leukemia. Cancer 1989, 63(2):289–294.
45.Shimamoto Y, Suga K, Nishimura J, Nawata H, Yamaguchi M: Major prognostic factors of Japanese patients with lymphoma‐type adult T‐cell leukemia. American journal of hematology 1990, 35(4):232–237.
46.Hoshi H, Nagamachi S, Jinnouchi S, Ohnishi T, Shigemi F, Watanabe K: Bone scintigraphy as a prognostic factor in patients with adult T-cell leukemia-lymphoma. Clinical nuclear medicine 1994, 19(11):992–995.
47.Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, Maeda T, Hirakata Y, Kamihira S, Tsukasaki K: Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. Journal of Clinical Oncology 1997, 15(5):1778–1785.
48.Utsunomiya A, Ishida T, Inagaki A, Ishii T, Yano H, Komatsu H, Iida S, Yonekura K, Takeuchi S, Takatsuka Y: Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leukemia research 2007, 31(7):915–920.
49.Shimamot Y, Suga K, Igarashi H, Nishimura J, Nawata H, Yamaguchi M: Differences between long-and short-term survivors with lymphoma type of adult T-cell leukemia. Leukemia & Lymphoma 1990, 2(5):301–305.
50.Graham RL, Burch M, Krause JR: Adult T-cell leukemia/lymphoma. Proceedings (Baylor University Medical Center) 2014, 27(3):235.
51.Tsukasaki K, Ikeda S, Murata K, Maeda T, Atogami S, Sohda H, Momita S, Jubashi T, Yamada Y, Mine M: Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leukemia research 1993, 17(2):157–166.
52.MC MP, Fernandez SA, Landes K, Huey D, Lairmore M, Niewiesk S: Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness. Virus research 2014, 189:206–213.
53.Mozhgani SH, Zarei-Ghobadi M, Teymoori-Rad M, Mokhtari-Azad T, Mirzaie M, Sheikhi M, Jazayeri SM, Shahbahrami R, Ghourchian H, Jafari M et al: Human T-lymphotropic virus 1 (HTLV–1) pathogenesis: A systems virology study. Journal of cellular biochemistry 2018, 119(5):3968–3979.
54.Du Y, Yamaguchi H, Hsu JL, Hung M-C: PARP inhibitors as precision medicine for cancer treatment. National Science Review 2017, 4(4):576–592.
55.Montoni A, Robu M, Pouliot E, Shah GM: Resistance to PARP-Inhibitors in Cancer Therapy. Frontiers in pharmacology 2013, 4:18.
56.Huseby S, Gausdal G, Keen TJ, Kjaerland E, Krakstad C, Myhren L, Bronstad K, Kunick C, Schwede F, Genieser HG et al: Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription. Cell death & disease 2011, 2:e237.
57.Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H: Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. Journal of Clinical Oncology 2019:JCO. 18.00501.